Immix Biopharma announced on September 11, 2025, that Nancy T. Chang, former CEO of Tanox, Inc. and a proven biotechnology leader, has joined its Board of Directors. This appointment occurred concurrent with her investment as a founding member of Goose Capital. Dr. Chang's extensive experience includes leading the invention and development of several FDA-approved drugs.
At Tanox, Dr. Chang and her team were instrumental in developing XOLAIR® (omalizumab) for severe asthma, TROGARZO® (ibalizumab-uiyk) for HIV, and EBGLYSS® (lebrikizumab-lbkz) for dermatitis. These therapies have collectively generated drug sales exceeding $5 billion. Tanox, Inc. was later acquired by Genentech/Roche for $919 million.
The addition of Dr. Chang to the board brings significant expertise in drug development, regulatory approval, and commercialization to Immix Biopharma. Her background is expected to be invaluable as NXC-201 progresses towards FDA approval and potential market launch.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.